Microfluidic and Solid-State Beta Camera In-Vitro Kinase Radioassay
- Technology Benefits
- Amount of required cell input is reduced by 1,000 times, allowing for experimentation on expensive of perishable samples. Amount of radioactivity is reduced due to lower amounts of radioactive elements used. Chips are cheaper to design and produce. Digital control makes assays more efficient, faster, and less labor-intensive.
- Technology Application
- Monitor kinase activity in precious samples such as biopsies or aspirate in experimental pre-clinical and clinical trials. Complementary diagnosis kit for cancer and other diseases. Assay platform works for both protein kinases and small molecule kinases. Studying signaling pathways in stem cells and/or patient samples in cancer and other disease biologies via protein kinase activity. Studying metabolic pathways in stem cells and/or patient samples in cancer and other disease biologies via small molecule kinase activity.
- Detailed Technology Description
- The invention uses a polydimethylsiloxane microfluidic platform with a solid state beta camera to measure kinase activity on a limited amount of patient samples. Miniaturizing the radiometric kinase assay brings several advantages over current radiometric assays. The amount of cell input required is reduced by 1,000 times over conventional assays. This allows for direct experimentation on clinical samples that are expensive or perishable. Also, the amount of radioactivity is reduced by at least one magnitude, alleviating radiation safety concerns. Further, the chips are inexpensive to custom design and produce. Finally, since most of the steps in the assay are under digital control, the performances of these assays are more efficient, faster, and less labor-intensive.
- Supplementary Information
- Patent Number: US6503509B1
Application Number: US2000513024A
Inventor: Vilen, Barbara J. | Cambier, John C.
Priority Date: 25 Feb 1999
Priority Number: US6503509B1
Application Date: 25 Feb 2000
Publication Date: 7 Jan 2003
IPC Current: A61P003702 | C07K001628 | G01N003350 | G01N0033566
US Class: 4241531 | 4241301 | 4241361 | 4241371 | 4241411 | 4241431 | 4241441 | 4241521 | 4241721 | 4241731 | 43507021 | 5140059 | 5140069 | 5140135 | 5140166 | 5140179 | 5140196 | 514885 | 5303871 | 5303873 | 5303881 | 5303882 | 53038822 | 5303887 | 53038873 | 5303891 | 5303896 | 514002 | 435071
Assignee Applicant: National Jewish Medical and Research Centernver
Title: Method for receptor desensitization
Usefulness: Method for receptor desensitization
Summary: The method is useful for treating any B cell-related disorder in which desensitization of the B cell antigen receptor would provide a therapeutic benefit, alone or in conjunction with another treatment. The B cell-disorders include autoimmune diseases selected from rheumatoid arthritis, systemic lupus erythematosus, insulin dependent diabetes mellitis, multiple sclerosis, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, and polyarteritis nodosa, allergic disorder, or disorders related to inflammatory responses, malignancies and transplantation. The method is also useful for research and diagnostic assays, and for screening putative regulatory compounds. The method of sensitizing a BCR is useful for increasing or inducing a B cell response to a given antigen or antigens, and can be used in a vaccine or adjuvant system.
Novelty: Desensitizing a receptor (e.g. B cell antigen receptor), useful for treating B cell-related disorders (e.g. autoimmune disease), by contacting it with a regulatory compound that dissociates or inhibits association of its components
- Industry
- Environmental/Green Technology
- Sub Category
- Solar Cell
- Application No.
- 9448178
- Others
-
State Of Development
A working prototype has been developed.
Background
There is a broad interest in targeting kinases for drug discovery and patient diagnosis. For example, kinases are important biomarkers in cancer diagnostics and treatment, or their activity can be monitored to determine the state of a cell (e.g. via PET imaging). This interest led to the development of numerous kinase assay technologies.
Generally, radiometric assays are adopted as the primary technology used by companies that provide kinase profiling services. However, they suffer from several limitations. The input amounts required for these assays make it difficult to study kinase activity on a small level. Also, these assays are labor-intensive, expensive, and are potentially hazardous to those handling the radioactive materials. Further, regulations that control the levels of a specific radioisotope that can be used may limit the desired work pace.Additional Technologies by these Inventors
- Statistical Comparison of Rank Lists and Molecular Profiles
- Treatment Of Melanoma With Ferroptosis Inducing Agents
Tech ID/UC Case
22119/2011-129-0
Related Cases
2011-129-0
- *Abstract
-
UCLA investigators have developed a miniaturized kinase assay that holds several advantages over conventional kinase radioassays. By utilizing a microfluidic platform with a solid state beta camera, this invention lowers the cell and radioactive input requirements and allows for improvements in cost, efficiency, speed, and labor.
- *IP Issue Date
- Sep 20, 2016
- *Principal Investigator
-
Name: Cong Fang
Department:
Name: Thomas Graeber
Department:
Name: Arion Xenofon Hadjioannou
Department:
Name: Hsian-Rong Tseng
Department:
Name: Nam Vu
Department:
Name: Yanju Wang
Department:
- Country/Region
- USA
